N/A N=117 Heterotopic Ossification Prophylaxis
Acetabular Fracture · Heterotopic Ossification
Primary: Number of Participants With Severe HO Formation — 3; 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=42 Prevention of Heterotopic Ossification With Arcoxia After Total Hip Replacement
Ossification, Heterotopic
Primary: Percentage of Participants With Heterotopic Ossification (HO) at 6 Months Postoperatively. — 38 percentage of participants
Phase 4 N=6 Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement
Osteoporosis
Primary: Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck — 100 percentage of participants
N/A N=69 Anterior Bridging Cage With Bone Substitute Versus Localized Autobone in Transforaminal Lumbar Interbody Arthrodesis
Stenosis · Fusion of Spine (Disease)
Primary: InCBB of Both Cages — 1.48; 1.43 score on a scale
Phase 3 N=68 Bone Properties in Hypoparathyroidism: Effects of PTH
Hypoparathyroidism
Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation
N/A N=147 Differences in Bone Cell Activity Between Rheumatoid Arthritis and Ankylosing Spondylitis
Rheumatoid Arthritis · Bone Resorption · Ankylosing Spondylitis
Primary: Osteoclast Differentiation Ex-vivo — 8; 12; 11; 5 OC/mm2
Phase 2 N=22 Phase 1/2a Study on Allogeneic Osteoblastic Cells Implantation in Delayed-Union Fractures
Long Bone Delayed-Union Fracture
Primary: Percentage of Responders at 6 Months (Efficacy of ALLOB) — 100 percent of patients
N/A N=29 OsteoStrux™ Collagen Ceramic Scaffold in Instrumented Lumbar Spine Fusion
Degenerative Changes · Stenosis · Spondylosis
Primary: Number of Posterolateral Gutters That Have Evidence of Arthrodesis (Fusion) at 3, 6, 12, and 24 Months, as Measured by X-rays. — 39; 34; 42; 36 Posterolateral Gutters
N/A N=22 Bone Augmentation Techniques in Extraction Sockets
Tooth Loss
Primary: Changes in Hard Tissue Composition — 35.82; 31.76 mm
N/A N=9 A Histomorphometric Analysis Following Sinus Augmentation Using Two Different Bone Graft Materials.
Missing Teeth
Primary: Percentage of New Vital Bone. — 16.33; 26.11; 30.5; 39.67 percentage of new vital bone
N/A N=54 Ridge Preservation Using a Ossix™ Bone vs Bio-Oss® Collagen
TEETH EXTRACTION
Primary: Percent Vital Bone Formation, — 26.8; 39.3 percentage of vital bone
Phase 4 N=85 Evaluation of Fusion Rate of Anterior Cervical Discectomy and Fusion (ACDF) Using Cervios ChronOs™ and Bonion™
Intervertebral Disk Degeneration · Intervertebral Disk Displacement · Ossification of Posterior Longitudinal Ligament
Primary: Bone Fusion With CT(Postoperative 6 Months) — 26; 28 participants
N/A N=15 ViviGen Cellular Bone Matrix for Hindfoot or Ankle Arthrodesis
Ankle Deformity · Ankle Arthritis
Primary: Union Rates — 23 joints fused
N/A N=38 Histologic Comparison of Healing After Tooth Extraction With Ridge Preservation Using Two Different Xenografts
Partial Edentulism
Primary: New Bone Formation at Extraction/Xenograft Site Measured by Histological Evaluation at 16-20 Weeks — 29.38; 32.05; 14.02; 16.56 Percent
N/A N=22 Assessment of nanOss Bioactive 3D in the Posterolateral Spine
Degenerative Disc Disease · Spinal Stenosis · Spondylolisthesis
Primary: Number of Patients With Fusion — 16 Participants
N/A N=104 Prospective, Multi-Center Clinical Outcomes Study Evaluating the chronOS Strip Combined With Bone Marrow Aspirate
Degeneration of Lumbar Intervertebral Disc
Primary: Posterolateral Fusion Success — 45 participants
N/A N=15 The Horizontal Ridge Augmentation Using Equine Xenograft and a Collagenated Porcine Cortical Lamina
Horizontal Ridge Deficiency
Primary: Change From Baseline in Radiological Bone Width Augmentation at 0 mm — 2.274 mm
N/A N=23 Humeral Shaft Pseudoarthrosis Treated With Bone Autograft Versus Platelet Rich Plasma
Pseudoarthrosis
Primary: Stans Scale — 2.7; 3.0 units on a scale
Phase 2 N=18 Cell Therapy for Craniofacial Bone Defects
Cleft Palate · Trauma
Primary: Bone Regeneration — 1.5; 3.3 implant sites
N/A N=29 Calcium Absorption in Patients With Rothmund-Thomson Syndrome
Rothmund-Thomson Syndrome
Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
Phase 3 N=23 Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
Osteoporosis, Postmenopausal · Osteoporosis · Osteoporosis Vertebral
Primary: Change From Baseline in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Envelope at Month 3 — 5.74; 18.66 percentage of MS/BS — p=<0.0001
Phase 3 N=26 Clinical Outcomes of ACL Reconstruction Augmented by an Injectable Osteoconductive/Osteoinductive Compound
ACL Injury
Primary: Number of Participants With Bone Tunnel Expansion — 0; 4; 10; 6 Participants
N/A N=30 Management of Traumatic Bone Defects in Tibial Plateau Fractures With Antibiotic-Impregnated Biodegradable Calcium Sulfate Beads: A Prospective Clinical Trial
Tibial Fractures · Intra-Articular Fractures · Fracture Fixation, Internal
Primary: Resorption of Study Device — 4 Participants
N/A N=167 Study Comparing BoneMaster Hydroxyapatite Coating With Plasma-sprayed Hydroxyapatite Coating on Acetabular Cups
Arthropathy of Hip
Primary: Record and Measure Bone Density Using DEXA Scans at 24 Months. — -11.0; 5.7 Net average BMD %change from baseline — p=0.4570
Phase 2 N=44 A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva
Fibrodysplasia Ossificans Progressiva
Primary: Period 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs — 24; 20; 2; 4 Participants
Phase 2 N=58 An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)
Fibrodysplasia Ossificans Progressiva
Primary: Parts A and B: Percentage of Flare-ups With No New Heterotopic Ossification (HO) at Week 12 — 64.3; 72.5 percentage of flare-ups
N/A N=11 Straumann Bone Ceramic Versus BioOss in Sinus Elevation
Jaw, Edentulous, Partially · Alveolar Bone Loss
Primary: Histologically Measured Bone to Implant Contact (BIC) — 64.552; 54.904 percentage of total surface
Phase 3 N=221 An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.
Fibrodysplasia Ossificans Progressiva
Primary: Annualized New Heterotopic Ossification (HO) — 9427.1; 23720.2 cubic millimeters (mm^3)
N/A N=66 Histological Evaluation of Healing Following Ridge Preservation Using a Combined Cortical/Cancellous Mineralized Freeze-Dried Bone Allograft
Alveolar Bone Loss
Primary: % Vital Bone Formation (Histological) — 26.4; 24.5; 28.8 percentage of total area
Phase 2 N=26 Bone Tissue Engineering Using Autologous Bone Repair Cell (BRC) Therapy for Sinus Floor Bone Augmentation
Tooth Loss
Primary: Bone Mineral Density of Bone Core — .79; .78 mg/mm^3